ArticleHeliyon2025
Reciprocal regulation between DNMT3A/3B and microRNAs miRs-299-3p/-30e is a causal factor for the downregulation of microRNAs targeting androgen receptor in prostate cancer.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Histone modifications across cancers: mechanisms, therapy and clinical translation.Molecular cancer · 2026Review
- Exercise-specific epigenetic effects on cardiovascular health.Clinical epigenetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Promoter hypermethylation is one of the events that downregulate microRNAs (miRNA), resulting in the differential expression of genes implicated in the progression of cancer. We previously reported that microRNAs (miRNA)-299-3p and -30e target androgen receptor (AR) and are downregulated in advanced prostate cancer (PCa). Here we report that miR-34c, an AR targeting miRNA and miR-299-3p, both are differentially downregulated in PCa cells from African American (AA) and Caucasian American (CA) patients due to disparate promoter hypermethylation in these miRNA genes. Methods: We performed bisulfite sequencing based promoter methylation analysis with or without treatment with DNA methyl transferase (DNMT) inhibitor 5-Aza-2'-deoxycytidine (AzaC). Luciferase reporter assays and RNA pulldown assays are conducted for miRNA -DNMT interaction analysis. We performed DNMT activity assays and ectopic expression of miRNAs to study their effects. Results: We observed higher promoter methylation of these miRNA genes in cells derived from an AA patient compared to cells of CA origin, which can be reversed through AzaC treatment. Differential expression and activity of DNMT3A and 3B are noted in PCa cells from AA and CA origins. Immunoprecipitation of Ago revealed bound DNMT3A and 3B mRNAs with miRs-299-3p and -30e in the RISC. Luciferase reporter assays confirmed binding of miRs-299-3p and -30e to the UTRs of DNMT3A and 3B mRNAs. Overexpression of miRs-299-3p and -30e downregulated DNMT3A/B mRNA and protein expression and DNMT activity of DNMTs. Ectopic expression of miR-299-3p restored expression of miRs-34c and -30e in PCa cells. Similarly, overexpression of miR-30e restored expression of miRs-34c and -299-3p. Conclusion: Our study provides evidence that ectopic expression of miRs-30e and -299-3p restore the loss of expression of miRs-299-3p and -34c miRNAs mediated by DNMT-induced promoter hypermethylation. This study establishes a feedback regulation between AR targeting miRNAs and DNMTs in PCa cells and provides an insight into the mechanism of the aberrant expression of AR in advanced PCa that is potentially mediated through the downregulation of miRs-299-3p, -34c and -30e and stabilization of expression and activities of DNMTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.